The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > OXiGENE, Inc.

OXiGENE, Inc.
Nasdaq: OXGN
Change
symbol:
     
 PROFILE
OXiGENE focuses on starving cancer tumors of oxygen. The firm's lead drug candidate, Combrestatin or CA4P, destroys blood vessels leading to tumors (known as antiangiogenesis), cutting off their supply of oxygen-rich blood needed to grow. It is developing CA4P with Bristol-Myers Squibb. Other candidates include Declopramide, which makes tumors more vulnerable to chemotherapy and radiation by inhibiting the DNA repair process, and Cordycepin, a leukemia treatment. Through joint venture ARCUS Therapetuics, OXiGENE and Peregrine Pharmaceuticals are exploring other antiangiogenesis programs. The firm also collaborates with universities in the US and Europe and other institutions to develop its drug pipeline.

 COMPETITION
Boston Life Sciences, Inc. (BLSI)
ImClone Systems Incorporated (IMCL)
Matrix Pharmaceutical, Inc. (MATX)

 STOCK ANALYSIS
 View by:
 Day 
 Day 
 Month 
 Month 
 Year 
 Year 
FURTHER ANALYSIS
• Advanced Charting
• Deals

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 1.70
1-Yr. Sales Growth: 30.8%
Employees: 15
Revenue per employee: $113,333.33

 KEY PEOPLE
• Bjorn Nordenvall
    CEO

 CONTACT INFO
321 Arsenal St.
Watertown, MA 02472
US
Phone: 617-673-7800
Fax: 617-924-9229
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001